relacorilant 150 MG, 1-Dose Pack
- RxCUI
- 2739555
- RxNorm name
- relacorilant 150 MG, 1-Dose Pack
- Display name
- relacorilant 150 MG, 1-Dose Pack
- Full name
- relacorilant 150 MG, 1-Dose Pack
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:03
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Lifyorli | RELACORILANT | Corcept Therapeutics Incorporated | 6fcebfb5-19d6-4f63-b852-999d68a13729 | 2026-03-26 | Warnings, Adverse reactions | 2739555 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 6fcebfb5-19d6-4f63-b852-999d68a13729 | relacorilant 150 MG, 1-Dose Pack | SY | 1 | These highlights do not include all the information needed to use LIFYORLI safely and effectively. See full prescribing information for LIFYORLI. LIFYORLI TM (relacorilant) capsules, for oral use Initial U.S. Approval: 2026 | 20260326 |
| 6fcebfb5-19d6-4f63-b852-999d68a13729 | relacorilant 150 MG, 1-Dose Pack | PSN | 1 | These highlights do not include all the information needed to use LIFYORLI safely and effectively. See full prescribing information for LIFYORLI. LIFYORLI TM (relacorilant) capsules, for oral use Initial U.S. Approval: 2026 | 20260326 |
| 6fcebfb5-19d6-4f63-b852-999d68a13729 | {1 (relacorilant 100 MG Oral Capsule) / 2 (relacorilant 25 MG Oral Capsule) } Pack | GPCK | 1 | These highlights do not include all the information needed to use LIFYORLI safely and effectively. See full prescribing information for LIFYORLI. LIFYORLI TM (relacorilant) capsules, for oral use Initial U.S. Approval: 2026 | 20260326 |